Immunopathogenesis of HIV infection.

The rate of progression of HIV disease may be substantially different among HIV-infected individuals. Following infection of the host with any virus, the delicate balance between virus replication and the immune response to the virus determines both the outcome of the infection, i.e. the persistence versus elimination of the virus, and the different rates of progression. During primary HIV infection, a burst of viremia occurs that disseminates virus to the lymphoid organs. A potent immune response ensues that substantially, but usually not completely, curtails virus replication. This inability of the immune system to completely eliminate the virus leads to establishment of chronic, persistent infection that over time leads to profound immunosuppression. The potential mechanisms of virus escape from an otherwise effective immune response have been investigated. Clonal deletion of HIV-specific cytotoxic T-cell clones and sequestration of virus-specific cytotoxic cells away from the major site of virus replication represent important mechanisms of virus escape from the immune response that favor persistence of HIV. Qualitative differences in the primary immune response to HIV (i.e. mobilization of a restricted versus broader T-cell receptor repertoire) are associated with different rates of disease progression. Therefore, the initial interaction between the virus and immune system of the host is critical for the subsequent clinical outcome.

[1]  S. Matsushita,et al.  Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees , 1990, Journal of virology.

[2]  J. Genescà,et al.  Clinical correlation and genetic polymorphism of the human immunodeficiency virus proviral DNA obtained after polymerase chain reaction amplification. , 1990, The Journal of infectious diseases.

[3]  R. Rose,et al.  The HIV core protein p24 inhibits interferon-gamma-induced increase of HLA-DR and cytochrome b heavy chain mRNA levels in the human monocyte-like cell line THP1. , 1991, Cellular immunology.

[4]  D. Carrigan,et al.  Suppression of human immunodeficiency virus type 1 replication by human herpesvirus-6. , 1990, The Journal of infectious diseases.

[5]  M. Strand,et al.  Inhibition of protein kinase C and anti-CD3-induced Ca2+ influx in Jurkat T cells by a synthetic peptide with sequence identity to HIV-1 gp41. , 1990, Journal of immunology.

[6]  M. de Carli,et al.  Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. , 1994, Science.

[7]  D. Ho HIV-1 viraemia and influenza , 1992, The Lancet.

[8]  M. Stevenson,et al.  Integration is not necessary for expression of human immunodeficiency virus type 1 protein products , 1990, Journal of virology.

[9]  A. Fauci,et al.  Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. , 1990, Immunology today.

[10]  P. Fultz,et al.  HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. , 1990, Journal of immunology.

[11]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[12]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[13]  D. Baltimore,et al.  Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression , 1990, The Journal of experimental medicine.

[14]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[15]  D. Giulian,et al.  Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1 , 1990, Science.

[16]  Q. Myrvik,et al.  Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. , 1990, AIDS research and human retroviruses.

[17]  Mauro Vaccarezza,et al.  Role of Lymphoid Organs in the Pathogenesis of Human Immunodeficiency Virus (HIV) Infection , 1994, Immunological reviews.

[18]  J. Phair Keynote address: variations in the natural history of HIV infection. , 1994, AIDS research and human retroviruses.

[19]  F. Miedema,et al.  Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. , 1994, Blood.

[20]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[21]  J. Justement,et al.  Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Fauci,et al.  The effect of cytokines and pharmacologic agents on chronic HIV infection. , 1992, AIDS research and human retroviruses.

[23]  A. Fauci,et al.  Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. , 1994, Science.

[24]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[25]  R. Gallo,et al.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Dietrich,et al.  ALTERED FOLLICULAR DENDRITIC CELLS AND VIRUS-LIKE PARTICLES IN AIDS AND AIDS-RELATED LYMPHADENOPATHY , 1985, The Lancet.

[27]  C V Jongeneel,et al.  Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. , 1996, Immunity.

[28]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[29]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[30]  P. Earl,et al.  Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. V. van Lier,et al.  AIDS pathogenesis: a dynamic interaction between HIV and the immune system. , 1990, Immunology today.

[32]  F. de Wolf,et al.  Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV‐1 phenotype , 1992, AIDS.

[33]  M. Baseler,et al.  Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals , 1989, Journal of virology.

[34]  Rolf M. Zinkernagel,et al.  Immunology Taught by Viruses , 1996, Science.

[35]  S E Macatonia,et al.  Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. , 1990, Immunology.

[36]  A. Fauci,et al.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.

[37]  Jerome A. Zack,et al.  HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.

[38]  J. Margolick,et al.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[39]  A. Fauci,et al.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. , 1989, Science.

[40]  J. Levy,et al.  Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals , 1990, Journal of virology.

[41]  T. Waldmann,et al.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.

[42]  S. Zolla-Pazner,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies , 1994, Journal of virology.

[43]  D. Montefiori,et al.  Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Kunsch,et al.  Infection of human fetal dorsal root ganglion glial cells with human immunodeficiency virus type 1 involves an entry mechanism independent of the CD4 T4A epitope , 1989, Journal of virology.

[45]  P. Easterbrook Non-progression in HIV infection. , 1994, AIDS.

[46]  C. Chang,et al.  Cytomegalovirus enhances lysis of HIV‐infected T lymphoblasts , 1989, International journal of cancer.

[47]  M P Dempsey,et al.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. , 1991, Science.

[48]  A. Fauci,et al.  Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Moore,et al.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.

[50]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[51]  P. Shapshak,et al.  Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[52]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[53]  J. Berzofsky,et al.  Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15 , 1995, The Journal of experimental medicine.

[54]  A. Fauci,et al.  Heat shock induction of HIV production from chronically infected promonocytic and T cell lines. , 1990, Journal of immunology.

[55]  A. Nel,et al.  HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism. , 1990, Journal of immunology.

[56]  P. Klenerman,et al.  Cytotoxic T Lymphocyte Lysis Inhibited by Viable HIV Mutants , 1995, Science.

[57]  John L. Sullivan,et al.  Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection , 1995 .

[58]  F. Miedema,et al.  Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. , 1990, The Journal of clinical investigation.

[59]  G. Pantaleo,et al.  Effect of anti‐V3 antibodies on cell‐free and cell‐to‐cell human immunodeficiency virus transmission , 1995, European journal of immunology.

[60]  Anthony S. Fauci,et al.  Toward an Understanding of the Correlates of Protective Immunity to HIV Infection , 1996, Science.

[61]  M. Gonda,et al.  Negative regulation of human immune deficiency virus replication in monocytes. Distinctions between restricted and latent expression in THP- 1 cells , 1990, The Journal of experimental medicine.

[62]  Y. Masuho,et al.  Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Richman,et al.  Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide. , 1990, The Journal of clinical investigation.

[64]  M. Clerici,et al.  A TH1-->TH2 switch is a critical step in the etiology of HIV infection. , 1993, Immunology today.

[65]  G. F. Burton,et al.  Follicular dendritic cells and human immunodeficiency virus infectivity , 1995, Nature.

[66]  M. Roederer,et al.  Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[67]  O. Strannegard,et al.  Zidovudine in the management of primary HIV‐1 infection , 1991, AIDS.

[68]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[69]  S. Buchbinder,et al.  Long‐term HIV‐1 infection without immunologic progression , 1994, AIDS.

[70]  A. Fauci,et al.  New concepts in the immunopathogenesis of HIV infection. , 1995, Annual review of immunology.

[71]  U. Sharma,et al.  Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells. , 1990, AIDS research and human retroviruses.

[72]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[73]  A. Fauci,et al.  Tracking HIV during disease progression. , 1994, Current opinion in immunology.

[74]  A. Fauci,et al.  Immunopathogenesis of the acquired immunodeficiency syndrome. , 1986, Annals of internal medicine.

[75]  J K Nicholson,et al.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. , 1986, Science.

[76]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[77]  R. Gallo,et al.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[78]  T. A. Hagan,et al.  Detection , Isolation , and Continuous Production of Cytopathic Retroviruses ( HTLV-III ) from Patients with AIDS and Pre-AIDS , 2022 .

[79]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[80]  C. Cavard,et al.  In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat. , 1990, The Journal of clinical investigation.

[81]  W. Greene,et al.  HIV-1, HTLV-1 and normal T-cell growth: transcriptional strategies and surprises. , 1989, Immunology today.

[82]  D. Ho,et al.  CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro , 1990, Journal of virology.

[83]  A. Fauci,et al.  Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1 , 1991, The Journal of experimental medicine.

[84]  C. Debouck,et al.  Activation of human immunodeficiency virus type 1 by DNA damage in human cells , 1988, Nature.

[85]  Fauci As AIDS: immunopathogenic mechanisms and research strategies. , 1987 .

[86]  C. Kufta,et al.  Specific tropism of HIV-1 for microglial cells in primary human brain cultures. , 1990, Science.

[87]  D. Littman,et al.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range , 1991, Journal of virology.

[88]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[89]  D. Montefiori,et al.  V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. , 1993, The Journal of clinical investigation.

[90]  S. Allen,et al.  Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1 , 1994, The Lancet.

[91]  D. Scadden,et al.  Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells , 1990, Journal of virology.

[92]  J. Armstrong,et al.  Retroviral infection of accessory cells and the immunological paradox in AIDS. , 1985, Immunology today.

[93]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[94]  K. Metzner,et al.  HIV suppression by interleukin-16 , 1995, Nature.

[95]  R. Cheynier,et al.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. , 1986, Science.

[96]  B. Franza,et al.  Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins , 1989, Journal of virology.

[97]  J. Berzofsky,et al.  Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals , 1989, Nature.

[98]  Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. , 1990, Disease markers.

[99]  R. Kettmann,et al.  A specific defect in CD3 gamma-chain gene transcription results in loss of T-cell receptor/CD3 expression late after human immunodeficiency virus infection of a CD4+ T-cell line. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[100]  D. Richman,et al.  Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells , 1990, The Journal of experimental medicine.

[101]  Karen L. Elkins,et al.  Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide , 1988, Nature.

[102]  Ying Sun,et al.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.

[103]  L. Montagnier,et al.  Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells. , 1994, The American journal of pathology.

[104]  A. Fauci,et al.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. , 1988, Science.

[105]  M. McGrath,et al.  Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. , 1991, The Journal of clinical investigation.

[106]  G. Pantaleo,et al.  Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[107]  S. J. Clark,et al.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. , 1991, The New England journal of medicine.

[108]  A. Fauci,et al.  Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[109]  J. Levy,et al.  Replication of HIV-1 in a wide variety of animal cells following phenotypic mixing with murine retroviruses. , 1990, Virology.

[110]  D. Ho,et al.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[111]  A. Fauci,et al.  The immunopathogenesis of human immunodeficiency virus infection. , 1993, The New England journal of medicine.

[112]  P. Berman,et al.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.

[113]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[114]  J. Strominger,et al.  Interaction between CD4 and class II MHC molecules mediates cell adhesion , 1987, Nature.

[115]  J. Goudsmit,et al.  Heat-shock induction of the human immunodeficiency virus long terminal repeat. , 1988, The Journal of general virology.

[116]  J. Justement,et al.  Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[118]  A. Fauci,et al.  Induction of expression of HIV in latently or chronically infected cells. , 1989, AIDS research and human retroviruses.

[119]  H. Stein,et al.  Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. , 1992, The American journal of pathology.

[120]  T. Merigan,et al.  Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. , 1988, AIDS research and human retroviruses.

[121]  D. Abrams,et al.  Persistent diffuse lymphadenopathy in homosexual men: endpoint or prodrome? , 1984, Annals of internal medicine.

[122]  M. Baseler,et al.  Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. , 1990, Annals of internal medicine.

[123]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1990, Nature.

[124]  C. Cheng‐Mayer,et al.  Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[125]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[126]  E. Gelmann,et al.  The Acquired Immunodeficiency Syndrome: An Update , 1985 .

[127]  C H Fox,et al.  The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. , 1989, Science.

[128]  E. Vittinghoff,et al.  The characterization of non‐progressors: long‐term HIV‐1 infection with stable CD4+ T‐cell levels , 1993, AIDS.

[129]  A. Collier,et al.  Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[130]  J. Justement,et al.  Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage , 1991, The Journal of experimental medicine.

[131]  S. Buchbinder,et al.  Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. , 1991, The Journal of infectious diseases.

[132]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[133]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[134]  J. Levy,et al.  Rapid CD8+ Cell Anti-HIV Activity Correlates with the Clinical State of the Infected Individual , 2003 .

[135]  A. Fauci,et al.  The role of lymphoid organs in the pathogenesis of HIV infection. , 1993, Seminars in immunology.

[136]  K. Sell,et al.  Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[137]  A. Fauci,et al.  The immunopathogenesis of HIV infection. , 1989, Advances in immunology.

[138]  A. Osterhaus,et al.  Impairment of in vitro immune responses occurs within 3 months after HIV-1 seroconversion. , 1990, AIDS.

[139]  J. Levy,et al.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. , 1984, Science.

[140]  J. Habeshaw,et al.  AIDS pathogenesis: HIV envelope and its interaction with cell proteins. , 1990, Immunology today.

[141]  M. Denis,et al.  Mycobacterium avium infection in HIV‐1‐infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens , 1994, Clinical and experimental immunology.

[142]  A. Fauci,et al.  Viral antigen stimulation of the production of human monokines capable of regulating HIV1 expression. , 1989, Journal of immunology.

[143]  Persephone Borrow,et al.  Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV , 1994, Nature.

[144]  M. Gale,et al.  Simian immunodeficiency virus is restricted to a subset of blood CD4+ lymphocytes that includes memory cells. , 1990, Journal of immunology.

[145]  M. Gurney,et al.  Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. , 1987, Science.

[146]  P. Herrlich,et al.  UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells , 1989, Journal of virology.

[147]  J. Hoxie,et al.  Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus. , 1985, Science.

[148]  P. Simmonds,et al.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers , 1990, Journal of virology.

[149]  S. Lipton,et al.  HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. , 1990, Science.

[150]  J. Levy,et al.  Detection of HIV in enterochromaffin cells in the rectal mucosa of an AIDS patient. , 1989, The American journal of gastroenterology.

[151]  W. Paul,et al.  Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[152]  R. Steinman,et al.  Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. , 1991, The Journal of clinical investigation.

[153]  F. Brun-Vézinet,et al.  Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS. , 1985, JAMA.

[154]  R. Kurth,et al.  Productive infection of both CD4+ and CD4- human cell lines with HIV-1, HIV-2 and SIVagm. , 1990, AIDS.

[155]  J. Laurence,et al.  Molecular interactions among herpesviruses and human immunodeficiency viruses. , 1990, The Journal of infectious diseases.

[156]  K. Nakamura,et al.  Intracellular distribution of the envelope glycoprotein of human immunodeficiency virus and its role in the production of cytopathic effect in CD4+ and CD4- human cell lines , 1990, Journal of virology.

[157]  J. Hoxie,et al.  Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. , 1986, Science.

[158]  E. Jaffe,et al.  Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow , 1988, Science.

[159]  J. Mellors,et al.  Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. , 1991, The Journal of infectious diseases.

[160]  B. Autran,et al.  A Th0/Th2-like function of CD4+CD7- T helper cells from normal donors and HIV-infected patients. , 1995, Journal of immunology.

[161]  E. Tschachler,et al.  Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6 , 1989, Nature.

[162]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[163]  S. Buus,et al.  The T-cell accessory molecule CD4 recognizes a monomorphic determinant on isolated Ia. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[164]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[165]  J. Groopman,et al.  Infection of nonlymphoid cells by human immunodeficiency virus type 1 or type 2 , 1990, Journal of virology.

[166]  M. McElrath,et al.  Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[167]  J. Lifson,et al.  Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection , 1994, The Lancet.

[168]  A. Fauci,et al.  Lymphoid organs function as major reservoirs for human immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[169]  Albrecht,et al.  The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes , 1989, Journal of virology.

[170]  T. Chou,et al.  Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. , 1992, AIDS research and human retroviruses.

[171]  A. Fauci,et al.  Induction of expression of human immunodeficiency virus in a chronically infected promonocytic cell line by ultraviolet irradiation. , 1989, AIDS research and human retroviruses.

[172]  J. Levy,et al.  HIV pathogenesis and long-term survival. , 1993, AIDS.

[173]  Z. Toossi,et al.  Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[174]  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1990, Disease markers.

[175]  C. Fox,et al.  Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. , 1991, The Journal of infectious diseases.

[176]  J. Justement,et al.  Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms , 1990, The Journal of experimental medicine.

[177]  J. McKeating,et al.  Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gpl20 , 1992 .

[178]  B. Haynes,et al.  Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[179]  D. Israëł-Biet,et al.  Human immunodeficiency virus production by alveolar lymphocytes is increased during Pneumocystis carinii pneumonia. , 1993, The American review of respiratory disease.

[180]  J. Sidtis,et al.  The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. , 1988, Science.

[181]  W. Rom,et al.  Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. , 1995, The Journal of clinical investigation.

[182]  B. Autran,et al.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway. , 1990, The Journal of clinical investigation.

[183]  M. Kieny,et al.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[184]  N. Brousse,et al.  Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. , 1990, The Journal of clinical investigation.

[185]  Lange,et al.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates , 1989, Journal of virology.

[186]  H. Lyerly,et al.  HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. , 1989, Journal of immunology.

[187]  C. June,et al.  No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120 , 1990, Nature.

[188]  D. Montefiori,et al.  Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques , 1994, Journal of virology.

[189]  J. Convit,et al.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. , 1991, Science.